Torna alla panoramica
NCT00867048

Strategic Timing of Antiretroviral Treatment

Base di dati: WHO (Importata da 03.05.2024)
Cambiato: 13 mar 2024, 01:00
Categoria di malattie:

Health conditions (Fonte di dati: WHO)

HIV Infection

Interventions (Fonte di dati: WHO)

Drug: All licensed antiretroviral medications

Inclusion/Exclusion Criteria (Fonte di dati: WHO)

Gender: All
Maximum age: N/A
Minimum age: 18 Years

INCLUSION CRITERIA:

- Signed informed consent

- HIV infection documented by a plasma HIV RNA viral load, rapid HIV test or any
licensed* ELISA test; and confirmed by another test using a different method including
but not limited to a rapid HIV test, Western Blot, HIV culture, HIV antigen, or HIV
pro-viral DNA at any time prior to study entry.

- Age greater than or equal to 18 years

- Karnofsky performance score greater than or equal to 80 (an indication that the
participant can perform normal activities)

- Perceived life expectancy of at least 6 months

- For women of child-bearing potential, willingness to use contraceptives as described
in the product information of the ART drugs they are prescribed

- Two CD4+ cell counts greater than 500 cells/mm(3) at least 2 weeks apart within 60
days before randomization

- The term licensed refers to an FDA-approved kit or, for sites located in
countries other than the United States, a kit that has been certified or licensed
by an oversight body within that country. Confirmation of the initial test result
must use a test method that is different than the one used for the initial
assessment.

EXCLUSION CRITERIA:

- Any previous use of ART or interleukin-2 (IL-2)

- Diagnosis of any clinical AIDS event before randomization (including esophageal
candidiasis and chronic Herpes simplex infection)

- Presence of HIV progression such as oral thrush, unexplained weight loss, or
unexplained fever

- Cardiovascular event (myocardial infarction, angioplasty, coronary-artery bypass
grafting, stroke) within 6 months before randomization

- Non-AIDS-defining cancer, excluding basal and squamous cell skin cancer, within 6
months before randomization

- Dialysis within 6 months before randomization

- Diagnosis of decompensated liver disease before randomization

- Current imprisonment, or compulsory detention (involuntary incarceration) for
treatment of a psychiatric or physical illness

- Current pregnancy or breastfeeding (a negative serum or urine pregnancy test is
required within 14 days before randomization for women of child-bearing potential)

Altri dati sulla sperimentazione nel registro primario dell’OMS

https://clinicaltrials.gov/ct2/show/NCT00867048

Altri dati sulla sperimentazione dalla banca dati dell’OMS (ICTRP)

https://trialsearch.who.int/Trial2.aspx?TrialID=NCT00867048
Altre informazioni sulla sperimentazione

Stato di reclutamento

Completed

Titolo scientifico (Fonte di dati: WHO)

Strategic Timing of AntiRetroviral Treatment

Tipo di sperimentazione (Fonte di dati: WHO)

Interventional

Disegno della sperimentazione (Fonte di dati: WHO)

Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Fase (Fonte di dati: WHO)

Phase 4

Punti finali primari (Fonte di dati: WHO)

Composite Endpoint of AIDS, Serious Non-AIDS Diagnoses, and All-cause Mortality

Punti finali secondari (Fonte di dati: WHO)

AIDs or AIDs Related Death;Specific Non-AIDS Diagnoses;Death, All-cause Mortality;Quality of Life- Mean Change From Baseline in a Visual Analog Scale (VAS) for Perceived Current Health;Transmission Risk Behavior Outcome 1;Change in Neurocognitive Function (in a Subset of Participants);Large Artery Elasticity (in a Subset of Participants);Rate of Lung Function Decline (in a Subset of Participants) Among;Changes in Bone Mineral Density (in a Subset of Participants) Measure 1;Transmission Risk Behavior Outcome 2;Small Artery Elasticity (in a Subset of Participants);Rate of Lung Function Decline (in a Subset of Participants) Among Non-smokers;Changes in Bone Mineral Density (in a Subset of Participants) Measure 2

Contatto per informazioni (Fonte di dati: WHO)

Please refer to primary and secondary sponsors

Risultati della sperimentazione (Fonte di dati: WHO)

Sintesi dei risultati

ancora nessuna informazione disponibile

Collegamento ai risultati nel registro primario

https://clinicaltrials.gov/ct2/show/results/NCT00867048

Informazioni sulla disponibilità dei dati dei singoli partecipanti

ancora nessuna informazione disponibile

Siti di esecuzione della sperimentazione

Paesi di esecuzione (Fonte di dati: WHO)

Argentina, Australia, Austria, Belgium, Brazil, Chile, Czech Republic, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, India, Ireland, Israel, Italy, Luxembourg, Malaysia, Mali, Mexico, Morocco, Nigeria, Norway, Peru, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, Switzerland, Thailand, Uganda, United Kingdom, United States

Contatto per maggiori informazioni sulla sperimentazione

Contatto per informazioni generali (Fonte di dati: WHO)

James D Neaton, PhD;Abdel Babiker, PhD;Jens Lundgren, MD, DMSc
University of Minnesota;Medical Research Council Clinical Trials Unit, London;Copenhagen HIV Programme

Contatto per informazioni scientifiche (Fonte di dati: WHO)

James D Neaton, PhD;Abdel Babiker, PhD;Jens Lundgren, MD, DMSc
University of Minnesota;Medical Research Council Clinical Trials Unit, London;Copenhagen HIV Programme

Altri numeri di identificazione delle sperimentazioni

Secondary ID (Fonte di dati: WHO)

U01AI068641
2008-006439-12
0603M83587
Torna alla panoramica